The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $645,369 in first-year total cost, median $322,685.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (02)]2
Most frequent institutions
- ELEUTHERIA PHARMACEUTICALS LLC1
- PHOENIX PHARMALABS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder1R41DA057430-01 | CIPPITELLI, ANDREATOLL, LAWRENCE R | PHOENIX PHARMALABS, INC., UT | $319,983 | ZDA1 |
| 2022 | Advancing mGlu1 positive allosteric modulators as therapeutics to facilitate abstinence in cocaine use disorder1R41DA057437-01 | WOLF, MARINA ELIZABETH | ELEUTHERIA PHARMACEUTICALS LLC, OR | $325,386 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.